Glenmark
A new way for a new world

July 26, 2016

To,
The Manager – Listing,
National Stock Exchange of India Ltd.
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Dear Sir/Madam,

Sub : **Glenmark Pharmaceuticals announces the successful closure of its USD 200 mn Reg S USD Bond. The bond was oversubscribed 8 times**

Further to our letter dated July 18, 2016, we would like to inform you that Glenmark Pharmaceuticals Limited has successfully closed the pricing of its debut U.S.$ 200 million 5-year non-call 3 year senior unsecured notes offering at 4.5% per annum, due 2021 (the 2016 Notes). The notes issuance follows a series of fixed income investor meetings in Asia and Europe, and was priced following strong demand aggregating U.S.$ 1.7 billion from a wide spectrum of institutional investors across Asia and Europe. The bonds were oversubscribed 8 times and the notes have been rated BB and BB by S&P and Fitch respectively. The proceeds from the issuance and sale of the Notes will be used for investment in Glenmark's wholly owned subsidiaries abroad, and will subsequently be applied to repay existing debt at the subsidiary level.

The offering is scheduled to close on August 1, 2016. Citi and HSBC acted as Joint Global Coordinators and ANZ, Barclays and DBS Bank Ltd acted as Joint Bookrunners and Joint Lead Managers to the offering.

You are requested to kindly take the same on record and oblige.

Thanking you,

Yours sincerely,
For **Glenmark Pharmaceuticals Limited**

Sanjay Kumar Chowdhary
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com